High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer

2019 ◽  
Vol 35 (2) ◽  
pp. 259-268 ◽  
Author(s):  
Andreas H Marx ◽  
Claudius Mickler ◽  
Guido Sauter ◽  
Ronald Simon ◽  
Luigi M Terracciano ◽  
...  
2010 ◽  
Vol 34 (5) ◽  
pp. 746-748 ◽  
Author(s):  
Brian D. Hayes ◽  
Aoife Maguire ◽  
Niamh Conlon ◽  
David Gibbons ◽  
Lai Mun Wang ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhenyan Gao ◽  
Huihua Cao ◽  
Xiang Xu ◽  
Qing Wang ◽  
Yugang Wu ◽  
...  

Abstract Background Lymphovascular invasion (LVI) is defined as the presence of cancer cells in lymphatics or blood vessels. This study aimed to evaluate the prognostic value of LVI in stage II colorectal cancer (CRC) patients with inadequate examination of lymph nodes (ELNs) and further combined LVI with the TNM staging system to determine the predictive efficacy for CRC prognosis. Adjuvant chemotherapy (ACT) was then evaluated for stage II CRC patients with LVI positivity (LVI+). Methods In order to avoid the effects of different ACT regimens, among 409 stage II patients, we chose 121 patients who received FOLFOX regimen and the 144 patients who did not receive ACT as the object of study. LVI was examined by hematoxylin-eosin (HE) staining. Kaplan-Meier analysis followed by a log-rank test was used to analyze survival rates. Univariate and multivariate analyses were performed using a Cox proportional hazards model. Harrell’s concordance index (C-index) was used to evaluate the accuracy of different systems in predicting prognosis. Results The LVI+ status was significantly associated with pT stage, degree of differentiation, tumor stage, serum CEA and CA19-9 levels, perineural invasion (PNI), tumor budding (TB), and KRAS status. The 5-year overall survival (OS) rate of stage II patients with < 12 ELNs and LVI+ was less than stage IIIA. Multivariate analyses showed that LVI, pT-stage, serum CEA and CA19-9 levels, PNI, TB, and KRAS status were significant prognostic factors for stage II patients with < 12 ELNs. The 8th TNM staging system combined with LVI showed a higher C-index than the 8th TNM staging system alone (C-index, 0.895 vs. 0.833). Among patients with LVI+, the ACT group had a significantly higher 5-year OS and 5-year disease-free survival (DFS) than the surgery alone (SA) group (5-year OS, 66.7% vs. 40.9%, P = 0.004; 5-year DFS, 64.1% vs. 36.3%, P = 0.002). Conclusions LVI is an independent prognostic risk factor for stage II CRC patients. Combining LVI with the 8th TNM staging system improved the predictive accuracy for CRC prognosis. ACT in stage II CRC patients with LVI+ is beneficial for survival.


2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e14544-e14544
Author(s):  
Sandro Barni ◽  
Fausto Petrelli ◽  
Ezio Pezzica ◽  
Mary Cabiddu ◽  
Andrea Coinu ◽  
...  

2012 ◽  
Vol 19 (12) ◽  
pp. 3706-3712 ◽  
Author(s):  
Johannes Betge ◽  
Peter Kornprat ◽  
Marion J. Pollheimer ◽  
Richard A. Lindtner ◽  
Andrea Schlemmer ◽  
...  

2017 ◽  
Vol 103 (1) ◽  
pp. 94-100 ◽  
Author(s):  
Catherine L. Forse ◽  
Mahdi Rahimi ◽  
Eleftherios P. Diamandis ◽  
Naziheh Assarzadegan ◽  
Heather Dawson ◽  
...  

In Vivo ◽  
2021 ◽  
Vol 35 (1) ◽  
pp. 525-531
Author(s):  
MASAHIRO KATAOKA ◽  
YASUMITSU HIRANO ◽  
TOSHIMASA ISHII ◽  
HIROKA KONDO ◽  
MASAHIRO ASARI ◽  
...  

2013 ◽  
Vol 44 (5) ◽  
pp. 697-705 ◽  
Author(s):  
Milo Horcic ◽  
Viktor H. Koelzer ◽  
Eva Karamitopoulou ◽  
Luigi Terracciano ◽  
Giacomo Puppa ◽  
...  

2015 ◽  
Vol 47 (4) ◽  
pp. 506-508 ◽  
Author(s):  
Tony Ibrahim ◽  
Khalil Saleh ◽  
Viviane Track-smayra ◽  
Nelly Ziade ◽  
Dalia Sarraf ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document